The Pharmacy Times® Colorectal Cancer Resource Center is a comprehensive resource for clinical news and expert insights on cancers that start in the colon or the rectum.
March 31st 2023
Experts note that pharmacists are well positioned to play a key role in precision oncology and molecular tumor boards.
Preventing and Managing Controlled Substance Diversion Across Health Care Settings
2.0 Credits / Law
View More
Preventing and Managing Controlled Substance Diversion Across Health Care Settings
2.0 Credits / Law
View More
Preventing and Managing Controlled Substance Diversion Across Health Care Settings
2.0 Credits / Law
View More
Oral Chemotherapy Parity Legislation: Opportunities for Cancer Care Equity
1.0 Credit / Law, Oncology
View More
Oral Chemotherapy Parity Legislation: Opportunities for Cancer Care Equity
1.0 Credit / Law, Oncology
View More
FDA Approves Bevacizumab Biosimilar for Six Types of Cancer
September 28th 2022Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More